Emerging Hub-Lite™ Model Serves Less Than Specialty Drugs

Pharmaceutical brands target different therapeutic areas, face a variety of challenges and have diverse needs. Manufacturers of specialty medicines—often injectable, high-cost, biologic or requiring cold-chain distribution that target rare diseases in small patient populations—require complex and extensive patient access and support services typically administered through full-service hubs. From a patient perspective, these hub services can be a lifeline to managing complicated, chronic conditions.

But what about those relatively less costly therapies—products in the $400 to $1,500 range that target serious, often life-threatening diseases with narrow patient populations as opposed to higher priced specialty drugs? Or, in other cases, diseases with very large populations?

This white paper and BONUS case study examines a changing landscape for less than specialty drugs which require high patient engagement, but not a one-size-fits-all hub experience. The actual case study reviews a retail product's resurrection from a failing launch using Triplefin's Hub-Lite™ model to differentiate the product across a variety of channels.